HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M900140-MCP200v1 8/10/2339    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Google Scholar Articles by Keshishian, H. Articles by Carr, S. A. PubMed PubMed Citation Articles by Keshishian, H. Articles by Carr, S. A. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 8:2339-2349, 2009.
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Quantification of Cardiovascular Biomarkers in Patient Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution^*,

Hasmik Keshishian^,, Terri Addona^,, Michael Burgess, D. R. Mani, Xu Shi^¶, Eric Kuhn, Marc S. Sabatine^||, Robert E. Gerszten^¶ and Steven A. Carr^,**

From the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142,
¶Cardiology Division and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, and
||Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115

Verification of candidate biomarkers requires specific assays to selectively detect and quantify target proteins in accessible biofluids. The primary objective of verification is to screen potential biomarkers to ensure that only the highest quality candidates from the discovery phase are taken forward into preclinical validation. Because antibody reagents for a clinical grade immunoassay often exist for a small number of candidates, alternative methodologies are required to credential new and unproven candidates in a statistically viable number of serum or plasma samples. Using multiple reaction monitoring coupled with stable isotope dilution MS, we developed quantitative, multiplexed assays in plasma for six proteins of clinical relevance to cardiac injury. The process described does not require antibodies for immunoaffinity enrichment of either proteins or peptides. Limits of detection and quantitation for each signature peptide used as surrogates for the target proteins were determined by the method of standard addition using synthetic peptides and plasma from a healthy donor. Limits of quantitation ranged from 2 to 15 ng/ml for most of the target proteins. Quantitative measurements were obtained for one to two signature peptides derived from each target protein, including low abundance protein markers of cardiac injury in the nanogram/milliliter range such as the cardiac troponins. Intra- and interassay coefficients of variation were predominantly <10 and 25%, respectively. The configured multiplex assay was then used to measure levels of these proteins across three time points in six patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy. These results are the first demonstration of a multiplexed, MS-based assay for detection and quantification of changes in concentration of proteins associated with cardiac injury in the low nanogram/milliliter range. Our results also demonstrate that these assays retain the necessary precision, reproducibility, and sensitivity to be applied to novel and uncharacterized candidate biomarkers for verification of proteins in blood.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. L. Hortin, S. A. Carr, and N. L. Anderson Introduction: Advances in Protein Analysis for the Clinical Laboratory Clin. Chem., February 1, 2010; 56(2): 149 - 151. [Full Text] [PDF]

				S. Makawita and E. P. Diamandis The Bottleneck in the Cancer Biomarker Pipeline and Protein Quantification through Mass Spectrometry-Based Approaches: Current Strategies for Candidate Verification Clin. Chem., February 1, 2010; 56(2): 212 - 222. [Abstract] [Full Text] [PDF]

				S. E. Abbatiello, D. R. Mani, H. Keshishian, and S. A. Carr Automated Detection of Inaccurate and Imprecise Transitions in Peptide Quantification by Multiple Reaction Monitoring Mass Spectrometry Clin. Chem., February 1, 2010; 56(2): 291 - 305. [Abstract] [Full Text] [PDF]